{{short description|Indian pharmaceutical company}} {{Multiple issues| {{More citations needed|date=January 2026}} {{Tone|date=March 2026}} }} {{Use dmy dates|date=June 2022}} {{Use Indian English|date=June 2022}} {{Infobox company | name = Laurus Labs Limited | logo = Laurus Labs Logo.png | logo_size = | image_caption = Laurus Labs manufacturing facility in Visakhapatnam | image = Laurus Labs Unit 3.jpg | type = Public | genre = | traded_as = {{NSE|LAURUSLABS}}<br />{{BSE|540222}} | predecessor = | successor = | founded = {{start date and age|2005}}<ref>{{cite news |title=Laurus Labs Ltd |url=https://www.bloomberg.com/profile/company/LAURUS:IN |accessdate=17 April 2020 |work=Bloomberg}}</ref> | founder = Satyanarayana Chava | defunct = | hq_location_city = Hyderabad, Telangana | hq_location_country = India<ref>{{cite news |title=Hyderabad-based Laurus Labs receives licence to manufacture 2DG |url=https://telanganatoday.com/hyderabad-based-laurus-labs-receives-licence-to-manufacture-2dg |access-date=27 January 2023 |work=Telangana Today |date=2 July 2021}}</ref> | num_locations = 6 | area_served = Global | key_people = {{ubl| *Satyanarayana Chava (CEO) *Vantaram Venkata Ravi Kumar (CFO)<ref>{{cite news |title=Laurus Labs banking on vertical integration to crack anti-HIV tenders and US formulations mkts |url=https://www.moneycontrol.com/news/business/companies/laurus-labs-banking-on-vertical-integration-to-crack-anti-hiv-tenders-and-us-formulations-mkts-4976561.html |accessdate=17 April 2020 |work=Moneycontrol}}</ref><ref>{{cite news |title=Laurus Labs: A hot startup in the pharma sector |url=https://www.forbesindia.com/article/hidden-gems/laurus-labs-a-hot-startup-in-the-pharma-sector/41063/1 |accessdate=17 April 2020 |work=Forbes India}}</ref>}} | industry = Pharmaceuticals | products = Formulations<br /> Active pharmaceutical ingredients Speciality Chemicals, Agro Chemicals | services = Custom synthesis<br /> Contract development and manufacturing organization<br /> Fermentation | revenue = {{increase}} {{INRConvert|6040|c}} (FY23)<ref name="fy23"/> | operating_income = | net_income = {{decrease}} {{INRConvert|796|c}} (FY23)<ref name="fy23">{{cite news |title=Laurus Labs Q4 net slumps |url=https://www.thehindu.com/business/laurus-labs-q4-net-slumps/article66785640.ece |access-date=27 June 2023 |work=The Hindu |date=27 April 2023 |language=en-IN}}</ref> | assets = | equity = | owner = | num_employees = 5,700 (2022)<ref>{{cite news |title=India's Laurus Labs says four employees died in fire incident |url=https://www.reuters.com/world/india/indias-laurus-labs-says-four-employees-dead-after-fire-incident-2022-12-27/ |access-date=27 January 2023 |work=Reuters |date=27 December 2022 |language=en}}</ref> | parent = | divisions = | subsidiaries = Laurus Synthesis {{Citation needed|date=March 2026}} | website = {{URL|https://www.lauruslabs.com}} | footnotes = }} '''Laurus Labs''' is an Indian multinational pharmaceutical and biotechnology company headquartered in Hyderabad. Its focus areas include active pharmaceutical ingredients (APIs), generic formulations, custom synthesis (CDMO), biotechnology,<ref>{{Cite web|date=2020-11-27|title=Laurus Labs Share Price: Company forays into Lucrative Biotech Space|url=https://www.zeebiz.com/companies/news-laurus-labs-share-price-company-forays-into-lucrative-biotech-space-142066|access-date=2020-11-27|website=Zee Business}}</ref> veterinary APIs and agrochemicals. The company was founded in 2005 by Satyanarayana Chava.<ref>{{Cite web |last=Sharma |first=Neetu Chandra |title=How Satyanarayana Chava Grew Laurus Labs |url=https://www.businesstoday.in/magazine/corporate/story/how-satyanarayana-chava-grew-laurus-labs-326080-2022-03-15 |access-date=2022-03-29 |website=Business Today |date=15 March 2022 |language=en}}</ref>
Laurus Labs has its eight manufacturing plants located at Visakhapatnam, Hyderabad and Bangalore. The manufacturing units have received one or more approvals from USFDA, WHO, NIP Hungary, KFDA, MHRA, TGA, and PMDA.<ref>{{Cite news|last=Trivedi|first=Isha|title=Laurus Labs strikes gold by moving up the value chain. But there's a steeper climb ahead.|work=The Economic Times|url=https://economictimes.indiatimes.com/prime/pharma-and-healthcare/laurus-labs-strikes-gold-by-moving-up-the-value-chain-but-theres-a-steeper-climb-ahead-/primearticleshow/77515258.cms|access-date=2020-10-19}}</ref> The company operates through its subsidiaries in Europe and United States and also offers its services in contract research, clinical research and analytical research through its R&D centers.{{citation needed|date=October 2020}} The R&D centres are based in Hyderabad, Visakhapatnam and United States.
== Business divisions == The company has 4 business divisions, which are generic formulation (FDF), generic APIs, contract development and manufacturing (CDMO)-Synthesis, biotechnology<ref>{{Cite web |date=2022 |title=Laurus Labs Limited: Annual Report 2021-22 |url=https://www.lauruslabs.com/Investors/PDF/Disclosures/LaurusLabsAnnualReportFY2021-22.pdf |access-date=16 June 2022 |website=Laurus Labs |page=3 }}</ref> and speciality chemicals.
=== Generic formulation (FDF) === In March 2020, Laurus Labs received US Food and Drug Administration approval to market hydroxychloroquine tablets. The company announced that it would supply hydroxychloroquine for clinical trials of preventive treatment of COVID-19.<ref>{{cite news |title=Coronavirus: Laurus Labs to supply Hydroxychloroquine for clinical trials in the US |work=Moneycontrol |url=https://www.moneycontrol.com/news/business/companies/coronavirus-laurus-labs-to-supply-hydroxychloroquine-for-clinical-trials-in-the-us-5082031.html |accessdate=17 April 2020}}</ref>
=== Generic APIs === Laurus Labs claims to be the "world's largest third party API supplier for anti-retrovirals" and has one of the largest<ref>{{Cite web |last=Laurus Labs |title=Investor Presentation |url=https://www.lauruslabs.com/Investors/PDF/Q3/LaurusLabsFinancialResultsQ3FY2020InvestorPresentation.pdf }}</ref> HiPotent API capacities in India<ref>{{cite news |title=Laurus Labs eyes bigger play in generic formulations segment |work=Times of India |url=https://timesofindia.indiatimes.com/business/india-business/laurus-labs-eyes-bigger-play-in-generic-formulations-segment/articleshow/73001890.cms |accessdate=17 April 2020}}</ref> The company also makes Dolutegravir/lamivudine/tenofovir, a medication for HIV/AIDS,<ref>{{cite news |title=Laurus Labs gets USFDA nod for HIV drug |work=Economic Times Health |url=https://health.economictimes.indiatimes.com/news/industry/laurus-labs-gets-usfda-nod-for-hiv-drug/67821291 |accessdate=17 April 2020}}</ref><ref>{{cite news |title=Laurus Labs is ready to flood the US with cheap HIV drugs |work=Livemint |url=https://www.livemint.com/Industry/BvlKjOnhLgiHu1xbLqmiSP/Laurus-Labs-is-ready-to-flood-the-US-with-cheap-HIV-drugs.html |accessdate=17 April 2020}}</ref> and hydroxychloroquine tablets, which are used to treat certain types of malaria.<ref>{{cite news |title=Laurus Labs gets USFDA nod for malaria tablets |work=The Hindu Business Line |url=https://www.thehindubusinessline.com/companies/laurus-labs-gets-usfda-nod-for-malaria-treatment-tablets/article26496219.ece |accessdate=17 April 2020}}</ref>
The company also manufactures oncology and cardiovascular APIs.<ref name=":1" /> Laurus Labs supplies (APIs) to nine of the 10 largest generic pharma companies in the world.<ref name=":1">{{Cite news |last=ET Bureau |date=29 March 2022 |title=ET Emerging Company of the Year 2021: Laurus Labs-A pharma company beats the virus trap to make it big |work=The Economic Times |url=https://economictimes.indiatimes.com/news/company/corporate-trends/emerging-company-of-the-year-laurus-labs-a-pharma-company-beats-the-virus-trap-to-make-it-big/articleshow/90481868.cms |access-date=2022-07-24}}</ref>
=== CDMO-Synthesis === Laurus Synthesis is the company's CDMO subsidiary.<ref>{{Cite news |last=Capital Market |first= |date=2021-01-12 |title=Laurus Labs arm incorporates wholly-owned unit |work=Business Standard India |url=https://www.business-standard.com/article/news-cm/laurus-labs-arm-incorporates-wholly-owned-unit-121011200273_1.html |access-date=2022-07-24}}</ref> The US, European Union and Japan are the three most important markets for Laurus Synthesis.<ref>{{Cite web |date=2022 |title=Laurus Labs Limited: Annual Report 2021-22 |url=https://www.lauruslabs.com/Investors/PDF/Disclosures/LaurusLabsAnnualReportFY2021-22.pdf |access-date=17 July 2022 |website=Laurus Labs |page=6 }}</ref>
=== Laurus Bio === Laurus Bio is the company's biotechnology subsidiary. Laurus Labs entered the biotechnology sector in 2020, by acquiring the Indian biotech company, Richcore.<ref name=":0">{{Cite web |last=Ramarathinam |first=Ashwin |date=2020-11-25 |title=Laurus Labs buys 73% stake in Biotech firm Richcore Lifesciences for Rs247 crore |url=https://www.livemint.com/companies/news/laurus-labs-buys-73-stake-in-biotech-firm-richcore-lifesciences-for-rs247-crore-11606311893776.html |access-date=2022-03-29 |website=mint |language=en}}</ref> Post the acquisition, Richcore was renamed to Laurus Bio Pvt Ltd, and became a subsidiary of Laurus Labs.<ref name=":0" /> As of 2022, Laurus Bio has put into operation a 180 kilolitre fermentation capacity in food proteins.<ref>{{Cite web |publisher=NSE Website - Investors Presentation of the company |title=Investors Presentation of the company |url=https://archives.nseindia.com/corporate/LAURUSLABS_30012023120401_LaurusLabsFinancialResultsQ3FY2023InvestorPresentation.pdf |id=[https://www.nseindia.com/get-quotes/equity?symbol=LAURUSLABS Quotes] |website=www.nseindia.com/}}</ref><ref>{{Cite web |date=2022 |title=Laurus Labs Limited: Annual Report 2021-22 |url=https://www.lauruslabs.com/Investors/PDF/Disclosures/LaurusLabsAnnualReportFY2021-22.pdf |access-date=13 July 2013 |website=Laurus Labs |page=7 }}</ref>
== References == {{Reflist}}
==External links== * {{Cite web|title=Laurus Labs subsidiary incorporates Laurus Ingredients; stock gains 1%|url=https://www.indiainfoline.com/article/news-top-story/laurus-labs-subsidiary-incorporates-laurus-ingredients-stock-gains-1-121011200323_1.html|access-date=2021-01-20|website=www.indiainfoline.com|language=en}} * {{Cite news|date=3 May 2021|title=Laurus Labs: Diversification to speed up in FY23; add on declines|work=Moneycontrol|url=https://www.moneycontrol.com/news/business/moneycontrol-research/laurus-labs-diversification-to-speed-up-in-fy23-add-on-declines-6847661.html|access-date=3 May 2021}} * {{Cite web|date=4 May 2021|title=Laurus Labs is already halfway past its $1 billion revenue target and has new capacities and products to back up its growth plan|url=https://www.moneycontrol.com/news/opinion/laurus-labs-1-billion-sales-target-needs-a-bit-of-luck-on-execution-6851581.html|access-date=4 May 2021|website=Moneycontrol}}
{{Nifty 200 companies}}
Category:Pharmaceutical companies of India Category:Pharmaceutical companies established in 2005 Category:Manufacturing companies based in Hyderabad, India Category:2005 establishments in Andhra Pradesh Category:Companies listed on the National Stock Exchange of India Category:Companies listed on the Bombay Stock Exchange